DiaMedica Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of DiaMedica Therapeutics generated cash of -$18,728,000, which is less than the previous year. Cash used in financing activities reached the amount of $36,842,000 last year. Net change in cash is therefore -$185,000.
Cash Flow
| 2014 | -3.75M | -31.32K | 1.67M |
|---|---|---|---|
| 2015 | -1.36M | -5.38K | 1.36M |
| 2016 | -3.02M | -6.89K | 4.59M |
| 2017 | -3.9M | -22K | 3.53M |
| 2018 | -5.69M | -50K | 21.21M |
| 2019 | -9.10M | -3.90M | 70K |
| 2020 | -9.18M | -16.13M | 28.84M |
| 2021 | -12.25M | -20.53M | 30.08K |
| 2022 | -11.51M | 11.53M | -6K |
| 2023 | -18.72M | -18.29M | 36.84M |
DMAC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.72M | 4.70M | 7.40M | 3.88M | 16.82M | 1.35M | 1.73M | 166.13K | 170.47K | 2.31M |
Operating activities | ||||||||||
Net income | -19.38M | -13.67M | -13.59M | -12.29M | -10.64M | -5.73M | -4.26M | -2.22M | -1.44M | -4.81M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 30K | 25K | 24K | 21K | 21K | 15K | 4K | 2.19K | 4.11K | 2.46K |
Stock-based compensation expense | 1.68M | 1.50M | 1.55M | 1.84M | 1.16M | 0 | 409K | 263.31K | 125.48K | 343.30K |
| Deferred income tax benefit | 1.68M | 1.50M | 1.55M | 1.84M | 1.16M | 0 | 409K | 263.31K | 125.48K | 343.30K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 48K | 210K | 483K | -43K | -700K | -27K | -42.35K | -2.78K | 4.75K |
Inventories | 0 | -48K | -210K | -483K | 0 | -372K | -756K | -32.30K | 0 | 0 |
Accounts payable | 192K | 225K | -590K | 917K | -301K | 372K | 248K | -599.06K | 0 | 0 |
Cash generated by operating activities | -18.72M | -11.51M | -12.25M | -9.18M | -9.10M | -5.69M | -3.9M | -3.02M | -1.36M | -3.75M |
Investing activities | ||||||||||
Purchases Of Investments | -69.41M | -45.68M | -69.81M | -39.74M | -12.91M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -24K | -81K | -22K | -47K | -2K | -50K | -22K | -6.89K | -5.38K | -31.32K |
Acquisitions Net | 0 | -11.61K | 2K | 16K | 13K | 0 | 0 | 1.5K | 0 | 0 |
Cash generated by investing activities | -18.29M | 11.53M | -20.53M | -16.13M | -3.90M | -50K | -22K | -6.89K | -5.38K | -31.32K |
Financing activities | ||||||||||
Common Stock Issued | 36.84M | 0 | 30.09M | 28.80M | 75K | 20.56M | 2.91M | 4.12M | 1.50M | 1.67M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -6K | -6K | -6 | -5K | -5K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 36.84M | -6K | 30.08K | 28.84M | 70K | 21.21M | 3.53M | 4.59M | 1.36M | 1.67M |
Net Change In Cash | -185K | 21K | -2.70M | 3.52M | -12.94M | 15.47M | -383K | 1.57M | -4.78K | -2.10M |
Cash at end of period | 4.54M | 4.72M | 4.70M | 7.40M | 3.88M | 16.82M | 1.35M | 1.73M | 165.69K | 203.78K |
| Data source | Data source | Data source | Data source | Data source | Data source |